ESMO Open

Papers
(The H4-Index of ESMO Open is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial960115767
Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer923351305
Table of Contents171127347
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆183
Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)100
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers96
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN92
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update85
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials82
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?77
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment74
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era74
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of rando72
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies72
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies69
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations67
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts63
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment62
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses61
Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis57
Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines54
A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study54
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer50
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France47
Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a pre-screening tool for clinical application47
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort46
How I treat biliary tract cancer45
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer44
The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration44
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis43
How to use liquid biopsies to treat patients with cancer41
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer41
Targeting immunoliposomes to EGFR-positive glioblastoma41
Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment38
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge38
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical37
Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study37
0.12476396560669